Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis
- PMID: 22088416
- DOI: 10.1016/j.clinthera.2011.10.019
Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis
Abstract
Background: Osteoarthritis (OA) is a debilitating condition characterized by chronic pain. Several pain medications are recommended, and patients frequently alternate among these medications.
Objectives: The purpose of this study was to examine the use of pain medications in clinical practice with respect to recommended guidelines. This objective was accomplished by evaluating patterns of switching, augmentation, and discontinuation after treatment initiation with select medications in patients with OA.
Methods: The LifeLink Health Plan Claims Database was used to select patients with OA (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 715.XX) who were newly prescribed (index event) nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, acetaminophen, tramadol, weak opioids, and strong opioids. Descriptive statistics, Kaplan-Meier analyses, and the COX proportional hazards model were used to assess therapy switching, augmentation, and discontinuation during the 12-month postindex period. Patterns of intraarticular injections and joint replacement surgeries among the cohorts were also evaluated.
Results: Substantial proportions of OA patients switched, augmented, or discontinued therapy during the postindex period. Rates of therapy switching, augmentation, and discontinuation, respectively, were significantly different (all P < 0.0001 for overall effects using log-rank tests) across the evaluated medication cohorts: NSAIDs, 22.3%, 6.7%, 93.2%; COX-2 inhibitors, 27.5%, 10%, 87.4%; acetaminophen, 46.0%, 6.5%, 98.7%; tramadol, 44.5%, 8.4%, 95.6%; weak opioids, 27.2%, 4.1%, 98.3%; and strong opioids, 41.1%, 3.3%, 97%. Therapy switching, augmentation, and discontinuation occurred within 2 months after treatment initiation in two thirds of patients and within 6 months in >90% of patients. The patterns of intraarticular injections were significantly different across treatment cohorts, as were the patterns of joint replacement surgeries (both P < 0.0001 for overall effects using log-rank tests), with average times to surgery that appeared longer with acetaminophen, NSAIDs, and COX-2 inhibitor initiators (416-447 days) than with tramadol and opioids (354-385 days).
Conclusions: Results indicate that therapy switching and discontinuation were frequent among OA patients initiating treatment with the currently recommended medication classes and might suggest suboptimal pain relief or potentially intolerable therapy-related side effects.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
-
Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain.Pain Pract. 2012 Jul;12(6):457-68. doi: 10.1111/j.1533-2500.2011.00524.x. Epub 2012 Jan 9. Pain Pract. 2012. PMID: 22230466
-
Association of age with analgesic use for back and joint disorders in outpatient settings.Am J Geriatr Pharmacother. 2006 Dec;4(4):306-15. doi: 10.1016/j.amjopharm.2006.12.009. Am J Geriatr Pharmacother. 2006. PMID: 17296536
-
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.Pharmacoepidemiol Drug Saf. 2004 May;13(5):277-87. doi: 10.1002/pds.909. Pharmacoepidemiol Drug Saf. 2004. PMID: 15133778
-
Osteoarthritis: a review of treatment options.Geriatrics. 2009 Oct;64(10):20-9. Geriatrics. 2009. PMID: 20726384 Review.
-
Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.Clin Drug Investig. 2012 Feb;32 Suppl 1:53-63. doi: 10.2165/11630080-000000000-00000. Clin Drug Investig. 2012. PMID: 23389876 Review.
Cited by
-
Impact of Non-steroidal Anti-inflammatory Drug Administration for 12 Months on Renal Function.Front Pain Res (Lausanne). 2021 May 26;2:644391. doi: 10.3389/fpain.2021.644391. eCollection 2021. Front Pain Res (Lausanne). 2021. PMID: 35295466 Free PMC article.
-
Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction.PLoS One. 2018 Aug 10;13(8):e0201884. doi: 10.1371/journal.pone.0201884. eCollection 2018. PLoS One. 2018. PMID: 30096158 Free PMC article.
-
A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis.J Manag Care Spec Pharm. 2021 Dec;27(12):1652-1660. doi: 10.18553/jmcp.2021.27.12.1652. J Manag Care Spec Pharm. 2021. PMID: 34818088 Free PMC article.
-
The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis.Clinicoecon Outcomes Res. 2018 Apr 6;10:213-222. doi: 10.2147/CEOR.S140208. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 29670383 Free PMC article.
-
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.BMJ. 2017 May 9;357:j1909. doi: 10.1136/bmj.j1909. BMJ. 2017. PMID: 28487435 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials